Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Markerless motion tracking and correction for PET, MRI, and simultaneous PET/MRI.

Slipsager JM, Ellegaard AH, Glimberg SL, Paulsen RR, Tisdall MD, Wighton P, van der Kouwe A, Marner L, Henriksen OM, Law I, Olesen OV.

PLoS One. 2019 Apr 19;14(4):e0215524. doi: 10.1371/journal.pone.0215524. eCollection 2019.

2.

Hybrid PET/MRI imaging in healthy unsedated newborn infants with quantitative rCBF measurements using 15O-water PET.

Andersen JB, Lindberg U, Olesen OV, Benoit D, Ladefoged CN, Larsson HB, Højgaard L, Greisen G, Law I.

J Cereb Blood Flow Metab. 2019 May;39(5):782-793. doi: 10.1177/0271678X17751835. Epub 2018 Jan 15.

3.

List-mode PET motion correction using markerless head tracking: proof-of-concept with scans of human subject.

Olesen OV, Sullivan JM, Mulnix T, Paulsen RR, Højgaard L, Roed B, Carson RE, Morris ED, Larsen R.

IEEE Trans Med Imaging. 2013 Feb;32(2):200-9. doi: 10.1109/TMI.2012.2219693. Epub 2012 Sep 19.

PMID:
23008249
4.

Methods for motion correction evaluation using 18F-FDG human brain scans on a high-resolution PET scanner.

Keller SH, Sibomana M, Olesen OV, Svarer C, Holm S, Andersen FL, Højgaard L.

J Nucl Med. 2012 Mar;53(3):495-504. doi: 10.2967/jnumed.111.095240. Epub 2012 Feb 13.

5.

Motion tracking for medical imaging: a nonvisible structured light tracking approach.

Olesen OV, Paulsen RR, Højgaard L, Roed B, Larsen R.

IEEE Trans Med Imaging. 2012 Jan;31(1):79-87. doi: 10.1109/TMI.2011.2165157. Epub 2011 Aug 18.

PMID:
21859614
6.

Motion tracking in narrow spaces: a structured light approach.

Olesen OV, Paulsen RR, Højgaar L, Roed B, Larsen R.

Med Image Comput Comput Assist Interv. 2010;13(Pt 3):253-60.

PMID:
20879407
7.

Comments on in vitro and in vivo studies of fluvoxamine-clozapine interaction.

Olesen OV, Linnet K.

J Clin Psychopharmacol. 2002 Oct;22(5):527-8. No abstract available.

PMID:
12352280
8.
9.
10.

Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.

Olesen OV, Poulsen B, Linnet K.

Ther Drug Monit. 2001 Feb;23(1):51-5.

PMID:
11206044
11.
13.

[Monitoring of serum olanzapine during antipsychotic treatment].

Linnet K, Olesen OV.

Ugeskr Laeger. 2000 Sep 4;162(36):4802-5. Danish.

PMID:
10994377
14.

Citalopram and breast-feeding: serum concentration and side effects in the infant.

Schmidt K, Olesen OV, Jensen PN.

Biol Psychiatry. 2000 Jan 15;47(2):164-5.

PMID:
10664835
15.

Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.

Licht RW, Olesen OV, Friis P, Laustsen T.

J Clin Psychopharmacol. 2000 Feb;20(1):110-2. No abstract available.

PMID:
10653223
16.
17.
18.
20.

Serum concentrations and side effects in psychiatric patients during risperidone therapy.

Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K.

Ther Drug Monit. 1998 Aug;20(4):380-4.

PMID:
9712460
21.
22.

Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.

Linnet K, Olesen OV.

Drug Metab Dispos. 1997 Dec;25(12):1379-82.

PMID:
9394027
23.
25.

Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria.

Hunsballe JM, Rittig S, Pedersen EB, Olesen OV, Djurhuus JC.

J Urol. 1997 Sep;158(3 Pt 1):830-6.

PMID:
9258093
26.
27.

Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant.

Jensen PN, Olesen OV, Bertelsen A, Linnet K.

Ther Drug Monit. 1997 Apr;19(2):236-9.

PMID:
9108657
28.

[Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].

Olesen OV, Starup G, Linnet K.

Ugeskr Laeger. 1996 Nov 25;158(48):6931-2. Danish.

PMID:
8984760
29.

[Citalopram and desmethylcitalopram for psychiatric patients].

Linnet K, Olesen OV.

Ugeskr Laeger. 1996 Aug 26;158(35):4920-3. Danish.

PMID:
8801700
31.

[Results of urinary control analyses of narcotic addicts on methadone therapy. An evaluation in the county of ]rhus in 1993].

Olesen OV, Linnet K, Rosenberg R.

Ugeskr Laeger. 1995 Feb 6;157(6):719-23. Danish.

PMID:
7701629
32.

Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study.

Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, Sørensen J, Bysted M, Christensen J, Rosenberg R.

Psychopharmacology (Berl). 1995 Feb;117(3):371-8.

PMID:
7770613
33.

Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients.

Kjølbye M, Thomsen K, Rogne T, Rehfelt E, Olesen OV.

Ther Drug Monit. 1994 Dec;16(6):541-7.

PMID:
7878691
34.

Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo.

Poulsen JH, Olesen OV, Larsen NE.

Ther Drug Monit. 1994 Apr;16(2):155-9.

PMID:
8009563
36.

[The effect of serum monitoring on concentration of perphenazine and zuclopenthixole].

Thomsen K, Olesen OV, Poulsen JH.

Ugeskr Laeger. 1993 Aug 9;155(32):2443-8. Danish.

PMID:
8356762
37.

Effect of low dietary sodium and potassium on lithium clearance in rats.

Thomsen K, Shalmi M, Olesen OV.

Miner Electrolyte Metab. 1993;19(2):91-8.

PMID:
8377730
38.

Perphenazine in breast milk and serum.

Olesen OV, Bartels U, Poulsen JH.

Am J Psychiatry. 1990 Oct;147(10):1378-9. No abstract available.

PMID:
2400007
40.
41.
42.
43.
44.

The effect of potassium on some nephrotoxic actions of lithium in rats.

Olesen OV.

Dan Med Bull. 1984 Aug;31(4):270-82. Review. No abstract available.

PMID:
6383737
45.

Effects of lithium on the structure of the rat kidney.

McAuliffe WG, Olesen OV.

Nephron. 1983;34(2):114-24.

PMID:
6866174
46.
47.
48.

A comparison between the natriuretic response to potassium in lithium- and amiloride-treated rats.

Olesen OV, Thomsen K.

Acta Pharmacol Toxicol (Copenh). 1981 May;48(5):382-9.

PMID:
7039225
49.
50.

Determination of lithium-induced impairment of distal water reabsorption.

Thomsen K, Olesen OV.

J Psychiatr Res. 1981;16(2):79-85. No abstract available.

PMID:
7265010

Supplemental Content

Loading ...
Support Center